Malik Rajesh's Form 4 filing
G1 Therapeutics, Inc. (GTHX) · filed Sep 16, 2022
- Accession no.
- 0001562180-22-006701
- Filed
- Sep 16, 2022, 4:31 PM ET
- Trade date
- Sep 13, 2022
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $282.7K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Malik RajeshCIK 0001706853 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2022 | Common Stock | MOption exerciseAcquired | +18,000 | $0.39 | +$7,020 | 91,207 | Direct | |
| Sep 13, 2022 | Common Stock | SSaleDisposed | −18,000 | $15.71F2 | −$282,745.8 | 73,207 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2022 | Common Stock | MOption exerciseDisposed | −18,000 | $0.00 | $0 | 21,439 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price represents the weighted average price with a low of $15.38 and a high of $16.20. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
Referenced by the price of 1 transaction in Table I.